Compass Pathways stock rises as 52-week data show lasting depression relief

Compass Pathways (NASDAQ:CMPS) climbed 4% on Wednesday after new 52-week data from the company's Phase III study of COMP360, its investigational oral psilocybin treatment for treatment-resistant depression (TRD). The data, from the open-label Part C portion of Study '005, showed sustained...